Setor K Kunutsor1, Samuel Seidu2,3, Kamlesh Khunti2,3. 1. Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Learning & Research Building (Level 1), Southmead Hospital, Southmead Road, Bristol BS10 5NB, UK. 2. Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK. 3. Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester LE5 4WP, UK.
Abstract
AIMS: There have been suggestions that statins may have a potential role in secondary prevention of venous thromboembolism (VTE) [which includes deep vein thrombosis (DVT) and pulmonary embolism (PE)], but the evidence is inconsistent. We aimed to evaluate the association between statin use and risk of recurrent VTE. METHODS AND RESULTS: We conducted a systematic review and meta-analysis of observational cohort studies. All relevant studies which reported associations between statin use and recurrent VTE outcomes were identified from MEDLINE, EMBASE, Web of Science, and manual search of bibliographies from inception to January 2017. Study specific relative risks (RRs) with 95% confidence intervals were aggregated using random effects models. Eight eligible studies comprising of 103 576 participants and 13 168 recurrent VTE outcomes were included in the pooled analysis. In pooled analysis of 7 studies, the RR for recurrent VTE was 0.73 (0.68-0.79) when comparing statin use with no use. There was no evidence of heterogeneity between contributing studies (I2=0%, 0-71%; P = 0.93). The RRs for recurrent PE (three studies) and DVT (two studies) comparing statin use with no statin use were 0.75 (95% CI: 0.58-0.96) and 0.66 (95% CI: 0.60-0.71) respectively. CONCLUSION: Available evidence from observational cohort studies suggests a beneficial effect of statin use on VTE recurrence. Well-designed intervention studies are needed to corroborate these findings. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: There have been suggestions that statins may have a potential role in secondary prevention of venous thromboembolism (VTE) [which includes deep vein thrombosis (DVT) and pulmonary embolism (PE)], but the evidence is inconsistent. We aimed to evaluate the association between statin use and risk of recurrent VTE. METHODS AND RESULTS: We conducted a systematic review and meta-analysis of observational cohort studies. All relevant studies which reported associations between statin use and recurrent VTE outcomes were identified from MEDLINE, EMBASE, Web of Science, and manual search of bibliographies from inception to January 2017. Study specific relative risks (RRs) with 95% confidence intervals were aggregated using random effects models. Eight eligible studies comprising of 103 576 participants and 13 168 recurrent VTE outcomes were included in the pooled analysis. In pooled analysis of 7 studies, the RR for recurrent VTE was 0.73 (0.68-0.79) when comparing statin use with no use. There was no evidence of heterogeneity between contributing studies (I2=0%, 0-71%; P = 0.93). The RRs for recurrent PE (three studies) and DVT (two studies) comparing statin use with no statin use were 0.75 (95% CI: 0.58-0.96) and 0.66 (95% CI: 0.60-0.71) respectively. CONCLUSION: Available evidence from observational cohort studies suggests a beneficial effect of statin use on VTE recurrence. Well-designed intervention studies are needed to corroborate these findings. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: John E Cornell; Cynthia D Mulrow; Russell Localio; Catharine B Stack; Anne R Meibohm; Eliseo Guallar; Steven N Goodman Journal: Ann Intern Med Date: 2014-02-18 Impact factor: 25.391
Authors: M Schmidt; S C Cannegieter; S A Johannesdottir; O M Dekkers; E Horváth-Puhó; H T Sørensen Journal: J Thromb Haemost Date: 2014-06-19 Impact factor: 5.824
Authors: N L Smith; L B Harrington; M Blondon; K L Wiggins; J S Floyd; C M Sitlani; B McKnight; E B Larson; F R Rosendaal; S R Heckbert; B M Psaty Journal: J Thromb Haemost Date: 2016-06-20 Impact factor: 5.824
Authors: Robert J Glynn; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Paul M Ridker Journal: N Engl J Med Date: 2009-03-29 Impact factor: 91.245
Authors: Sara Biere-Rafi; Barbara A Hutten; Alessandro Squizzato; Walter Ageno; Patrick C Souverein; Anton de Boer; Victor E A Gerdes; Harry R Büller; Pieter W Kamphuisen Journal: Eur Heart J Date: 2013-02-08 Impact factor: 29.983
Authors: Lana A Castellucci; Chris Cameron; Grégoire Le Gal; Marc A Rodger; Doug Coyle; Philip S Wells; Tammy Clifford; Esteban Gandara; George Wells; Marc Carrier Journal: BMJ Date: 2013-08-30
Authors: Cu Dinh Nguyen; Charlotte Andersson; Thomas Bo Jensen; Anne Gjesing; Anne-Marie Schjerning Olsen; Carolina Malta Hansen; Harry Büller; Christian Torp-Pedersen; Gunnar H Gislason Journal: BMJ Open Date: 2013-11-07 Impact factor: 2.692
Authors: Christian T Ruff; Marc S Sabatine; Nicholas A Marston; Yared Gurmu; Giorgio E M Melloni; Marc Bonaca; Baris Gencer; Peter S Sever; Terje R Pedersen; Anthony C Keech; Carolina Roselli; Steven A Lubitz; Patrick T Ellinor; Michelle L O'Donoghue; Robert P Giugliano Journal: Circulation Date: 2020-03-29 Impact factor: 29.690
Authors: Setor K Kunutsor; Samuel Seidu; Ashley W Blom; Kamlesh Khunti; Jari A Laukkanen Journal: Eur J Epidemiol Date: 2017-07-17 Impact factor: 8.082
Authors: Fernanda A Orsi; Joseph S Biedermann; Marieke J H A Kruip; Felix J van der Meer; Frits R Rosendaal; Astrid van Hylckama Vlieg; Mettine H A Bos; Frank W G Leebeek; Suzanne C Cannegieter; Willem M Lijfering Journal: J Thromb Haemost Date: 2019-02-03 Impact factor: 5.824
Authors: Dana Dlouha; Milan Blaha; Eva Rohlova; Jaroslav A Hubacek; Vera Lanska; Jakub Visek; Vladimir Blaha Journal: Genes (Basel) Date: 2021-10-12 Impact factor: 4.096